CELA3A

Across TCGA pan-cancer cohorts, CELA3A Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CELA3A data layer compared with 20 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CELA3A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CELA3A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, SKCM, and HNSC are the cancer types where CELA3A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.128	0.684	<.001	27	view →
SKCM	OS	Median	All	0.216	0.781	.001	15	view →
HNSC	DFS	Median	III,IV	0.128	0.680	.005	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
UCEC	DFS	Median	All	1.000	0.624	.029	6	view →
COAD	OS	Median	All	0.255	0.688	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CELA3A–LUAD (DFS)

Open the LUAD breakdown →